Key Highlights

Risk & Performance

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

1 recruiting

Phase 1

5(83.3%)

Early Phase 1

1(16.7%)

6Total

Phase 1(5)

Early Phase 1(1)

Loading network data...

Showing 6 of 6 trials

A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas

Role: collaborator

A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies

Role: collaborator

RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma

Role: collaborator

RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies

Role: collaborator

RN1201 Injection in the Treatment of Antibody-Mediated Diseases

Role: collaborator

A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors

Role: collaborator

All 6 trials loaded